Company intelligence / Profile preview
Mesogen Inc.
The Woodlands, Texas, United Statesmesogen.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Mesogen has developed a transplantable Retinal Pigmented Epithelium (RPE) patch to cure Macular Degeneration Blindness using autologous bone marrow-derived stem cells. The technology carries no teratoma tumor risk and requires no immunosuppression. They are also developing custom human kidneys from patients' own stem cells.[1][2]
- Therapeutic areas
- OphthalmologyNephrology
- Modalities
- Stem cell therapyCell-based therapiesTissue engineering
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Mesogen Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mesogen Inc..